Le diabète non-insulinodépendant : une affection en expansion. Importance d’une approche multidisciplinaire
Tài liệu tham khảo
Lefebvre, 1988, Clinical forms of diabetes mellitus, 1
Sinha, 2002, Prevalence of impaired glucose tolerance among children and adolescents with marked obesity, N Engl. J. Med, 346, 802, 10.1056/NEJMoa012578
Scheen, 1996, Le diabète non insulinodépendant : de la physiopathologie au traitement, Bulletin et Mémoires de l’Académie royale de Médecine de Belgique, 757, 395
Scheen, 2000, Insulin resistance vs insulin deficiency : which comes first ? The old question revisited, 101
World Health Organization, 2002, The World Health Report 2002. Reducing risks, promoting healthy life, WHO publications
Barker, 2001, Type 2 diabetes : the thrifty phenotype, Brit. Med. Bull., 60, 1, 10.1093/bmb/60.1.1
Barker, 1999, Signalisation de l’insuline et mécanismes moléculaires de l’insulinorésistance, Journées de Diabétologie, 125
Lefebvre, 2003, Diabetes prevention and strategic action, IDF Diabetes Atlas, 301
Zimmet, 1997, The global NIDDM epidemic. Treating the disease and ignoring the symptom. Diabetologia, 1996, 39, 1247-1248. Traduction française : Le diabète non insulinodépendant : Une pandémie. Traiter la maladie et ignorer le symptôme, Diabetes & Metabolism (Paris), 23, 448
Hancu, 2002, 286
American Diabetes Association, 2003, Standards of medical care for patients with diabetes mellitus, Diabetes Care, 26, S33, 10.2337/diacare.26.2007.S33
Agence Française De Sécurité Sanitaire Des Produits De Santé, 1999, Traitement médicamenteux du diabète de type 2. Recommandations : texte long, argumentaire, Diab Metab, 25, 1
Scheen, 2000, Treatment of Diabetes Mellitus, 685
Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N. Engl. J. Med., 348, 383, 10.1056/NEJMoa021778
Uk Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
Uk Prospective Diabetes Study (UKPDS) Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 703, 10.1136/bmj.317.7160.703
2002, MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals : a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Khamaisi, 2003, Thiazolidinediones in cardiovascular risk in type 2 diabetes mellitus, 193
Ravid, 1996, Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study, Arcli. Intern. Med., 156, 286, 10.1001/archinte.1996.00440030080010
Gaede, 1999, Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study, Lancet, 353, 617, 10.1016/S0140-6736(98)07368-1
Scheen, 2002, New antiobesity agents in type 2 diabetes : Overview of clinical trials with sibutramine and orlistat, Diabetes Met ab (Paris), 28, 437
Hollander, 1998, Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomised double-blind study, Diab Care, 27, 1288, 10.2337/diacare.21.8.1288
Dailey, 2001, Patient compliance and persistence with antihyperglycemic drug regimens : Evaluation of a Medicaid patient population with type 2 diabetes mellitus, Clinical Therapeutics, 23, 1311, 10.1016/S0149-2918(01)80110-7
Pan, 1997, Effect of diet and exercise in preventing NIDDM in people with impaired glucose tolerance : the Da Quing IGT and Diabetes Study, Diab. Care, 20, 537, 10.2337/diacare.20.4.537
Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med., 344, 1343, 10.1056/NEJM200105033441801
Diabetes Prevention Programme Research Group, 2002, Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med., 346, 393, 10.1056/NEJMoa012512
Chiasson, 2002, for the Stop-NiDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5
International Diabetes Federation, 2003, Global Strategic Plan to Raise Awareness of Diabetes, 20